NOVEL DRUG DISCOVERY & DEVELOPMENT (NDDD)
The NDDD team has developed a pipeline of 11 highly differentiated and innovative new chemical entities in focused therapy areas of CNS disorders, Oncology, Immunology, Pain and Metabolic disorders.
Key Targets & Status
- Immunology: Clinical Phase-I study successfully completed in Europe and two Phase-II studies in Europe are ongoing (Rheumatoid Arthritis and Psoriasis). The targets have the potential to be first-in-class in chosen therapy area.
- Endocrine: Clinical Phase-I study successfully completed in Europe and has met the approvable primary end-point. Results for Phase-II will soon be ready and further studies will be conducted in India.
- Oncology: Clinical Phase-I study has been successfully completed in Europe on terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer). Phase-II study will soon commence in India for treating refractory type of Lung cancer.